Changes in activatory and inhibitory natural killer (NK) receptors may induce progression to multiple myeloma: implications for tumor evasion of T and NK cells.
Metadatos
Mostrar el registro completo del ítemAutor
Bernal, Monica; Garrido, Pilar; Jiménez, Pilar; Carretero Coca, Rafael; Almagro, Manuel; López, Pilar; Navarro, Pilar; Garrido Torres-Puchol, Federico; Ruiz-Cabello Osuna, FranciscoEditorial
Elsevier
Materia
NK cell Prognosis Cancer Multiple Myeloma
Fecha
2009-10Referencia bibliográfica
Hum Immunol. 2009 Oct;70(10):854-7. doi: 10.1016/j.humimm.2009.07.004. Epub 2009 Jul 4.
Patrocinador
Servicio de Anàlisis Clìnicos e Inmunologìa, Hospital Universitario Virgen de las Nieves, Granada, Spain; Servicio de Hematologìa y Hemoterapia, Hospital Universitario Virgen de las Nieves, Granada, SpainResumen
The molecular basis of monoclonal gammopathy of undetermined significance (MGUS) progression to a malignant monoclonal gammopathy remains poorly understood. It was recently suggested that this process involves the suppression of innate and adaptive immunity. In this study, we examined immunogenic differences in bone marrow plasma cells among individuals without gammopathy (controls) and patients with MGUS, multiple myeloma (MM), and plasma cell leukemia. We detected differences in major histocompatibility complex (MHC) class I expression, MHC class I chain-related molecule A, and CD95 that were more evident between MGUS and MM samples; there appeared to be a critical imbalance between natural killer (NK)-cell activating and inhibitory signals during the transition from MGUS to MM. Our results indicate that the human leukocyte antigen (HLA) class I(bright), MICA(dim/-), and CD95(dim/-) immunophenotype reported in myeloma cells may result from an extensive interaction of malignant cells with cytotoxic T and NK cells and appears to be immunoedited for the evasion of immunosurveillance.





